Effect of alpha lipoic acid on epithelial mesenchymal transition in SKOV-3 cells

Background: Ovarian cancer is the fifth leading cause of cancer-related death in women. Patients are usually diagnosed with advanced tumor metastass. Epithelial over cancer cells spread from primary tumor by undergoing epithelial mesenchymal transition (EMT). It has been suggested that alpha lipoic acid (ALA), a natural antioxidant lipophilic compound, reduces the oxidative stress by causing apoptosis and inhibition of proliferation of cell in cancer cells. The aim of our study was to establish a transforming growth factor 81 (TGF 81) dependent epithelial mesenchymal transition model in the SKOV-3 ovarian adenocarcinoma cell line which is an epithelial subtype of ovarian cancer and to investigate the effects of alpha lipoic acid on EMT and ovarian cancer migration.Methods: For establish an EMT model, SKOV-3 cells were treated with different dose of TGF 81 and XTT cell viability kit was used to find IC 50 dose of ALA. Four different groups that are control, TGF 81, ALA and ALA + TGF 81 were created. Changes in the expression of genes related to EMT markers that are E-cadherin, vimentin, Snail, Slug, Twist and Zeb were analyzed with quantitative real-time PCR. These proteins were determined with the immunocytochemistry method. The migration capacity was analyzed with wound healing assay. Matrigel invasion capacity test was used to show invasion and colonization test to show colonization.Results: The dose of TGF 81 was determined 100 ng/ml at 72 h, the IC50 dose of ALA 219.033 mu M at 48 h was determined. EMT markers in the TGF 81 group were compatible with EMT and it was shown to inhibit EMT in the groups given ALA. According to wound healing, colonization and invasion experiments, proliferation and invasion increased in TGF 81 group, but decreased in ALA and combined groups (p < 0.05).Conclusion: These results indicate that ALA suppresses the metastasis of ovarian cancer cells by regulating EMT, implying that ALA might be a potential therapeutic agent for the treatment of ovarian cancer.